We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
Read MoreHide Full Article
Pfizer (PFE - Free Report) is launching a new direct-to-consumer (DTC) website called PfizerForAll, which will allow patients to order its marketed products for COVID-19, influenza and migraine directly.
How the New PFE Platform Works
The digital pharmacy will offer a convenient home delivery option for Pfizer medicines through third-party pharmacies. The new website also provides access to scheduling same-day appointments with independent healthcare professionals, either in-person or online.
PFE is also offering adult users to check whether they’re eligible for certain vaccines and, if so, make an appointment at a nearby pharmacy to get selected shots. The DTC platform will put all of the company’s savings and support programs in one place, potentially helping patients find options for which they’re eligible.
The digital platform is not just limited to Pfizer’s products — users can use the site to schedule a COVID-19 vaccination with Moderna’s vaccine just as easily as Pfizer’s.
The DTC platform will operate within the US healthcare system, allowing patients to use their existing insurance and pharmacy benefits. The services offered through PfizerForAll are being provided in partnership with healthcare organizations, which include UpScriptHealth, Alto Pharmacy and Instacart.
PFE Stock Performance
Year to date, Pfizer’s shares have inched up 0.1% compared with the industry’s 27% rise.
Image Source: Zacks Investment Research
Other Drugmakers with DTC Platforms
Pfizer is not the only one with its own DTC platform. At the start of this year, Eli Lilly (LLY - Free Report) launched the digital pharmacy LillyDirect to help patients order medicines for obesity, migraine and diabetes directly. Unlike PfizerForAll, LillyDirect is currently limited to providing access only to LLY’s marketed drugs.
On Tuesday, Lilly announced that it is launching single-dose vials of obesity drug Zepbound, which are priced at least 50% lower than the list price of all similar medications for obesity. This move is aimed at easing the manufacture of Zepbound, which is currently facing supply shortages in response to higher demand.
Our Take
These online platforms by Lilly and Pfizer should boost their respective top line. The use of online platforms would help drugmakers communicate with their consumers directly and understand their needs better. Direct access to patients could also help circumvent players like pharmacy benefit managers that drugmakers say reduce their revenue and hurt patient access.
In the past 60 days, estimates for Bioventus’ 2024 earnings per share have risen from 27 cents to 40 cents. Estimates for 2025 have increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 83.3%.
BVS’ earnings beat estimates in three of the last four quarters and missed the mark on one occasion. Bioventus delivered a four-quarter average earnings surprise of 102.86%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have improved from $1.24 to 48 cents. Estimates for 2025 have improved from $1.71 to $1.51 during the same period. Year to date, Fulcrum Therapeutics’ shares have rallied 31.2%.
Earnings of Fulcrum Therapeutics beat estimates in each of the last four quarters. Fulcrum delivered a four-quarter average earnings surprise of 393.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
Pfizer (PFE - Free Report) is launching a new direct-to-consumer (DTC) website called PfizerForAll, which will allow patients to order its marketed products for COVID-19, influenza and migraine directly.
How the New PFE Platform Works
The digital pharmacy will offer a convenient home delivery option for Pfizer medicines through third-party pharmacies. The new website also provides access to scheduling same-day appointments with independent healthcare professionals, either in-person or online.
PFE is also offering adult users to check whether they’re eligible for certain vaccines and, if so, make an appointment at a nearby pharmacy to get selected shots. The DTC platform will put all of the company’s savings and support programs in one place, potentially helping patients find options for which they’re eligible.
The digital platform is not just limited to Pfizer’s products — users can use the site to schedule a COVID-19 vaccination with Moderna’s vaccine just as easily as Pfizer’s.
The DTC platform will operate within the US healthcare system, allowing patients to use their existing insurance and pharmacy benefits. The services offered through PfizerForAll are being provided in partnership with healthcare organizations, which include UpScriptHealth, Alto Pharmacy and Instacart.
PFE Stock Performance
Year to date, Pfizer’s shares have inched up 0.1% compared with the industry’s 27% rise.
Image Source: Zacks Investment Research
Other Drugmakers with DTC Platforms
Pfizer is not the only one with its own DTC platform. At the start of this year, Eli Lilly (LLY - Free Report) launched the digital pharmacy LillyDirect to help patients order medicines for obesity, migraine and diabetes directly. Unlike PfizerForAll, LillyDirect is currently limited to providing access only to LLY’s marketed drugs.
On Tuesday, Lilly announced that it is launching single-dose vials of obesity drug Zepbound, which are priced at least 50% lower than the list price of all similar medications for obesity. This move is aimed at easing the manufacture of Zepbound, which is currently facing supply shortages in response to higher demand.
Our Take
These online platforms by Lilly and Pfizer should boost their respective top line. The use of online platforms would help drugmakers communicate with their consumers directly and understand their needs better. Direct access to patients could also help circumvent players like pharmacy benefit managers that drugmakers say reduce their revenue and hurt patient access.
Zacks Rank
Pfizer carries a Zacks Rank #3 (Hold).
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
Our Key Picks Among Biotech Stocks
A couple of better-ranked stocks include Bioventus (BVS - Free Report) and Fulcrum Therapeutics (FULC - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Bioventus’ 2024 earnings per share have risen from 27 cents to 40 cents. Estimates for 2025 have increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 83.3%.
BVS’ earnings beat estimates in three of the last four quarters and missed the mark on one occasion. Bioventus delivered a four-quarter average earnings surprise of 102.86%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have improved from $1.24 to 48 cents. Estimates for 2025 have improved from $1.71 to $1.51 during the same period. Year to date, Fulcrum Therapeutics’ shares have rallied 31.2%.
Earnings of Fulcrum Therapeutics beat estimates in each of the last four quarters. Fulcrum delivered a four-quarter average earnings surprise of 393.18%.